Skip to main content
. 2022 Feb 14;15(5):999–1006. doi: 10.1093/ckj/sfac045

Table 2.

Outcomes and biochemical parameters at 3 month follow-up

All patients COVID-19 patients Control group P
Death, n/N (%) 8/944 (0.8) 7/523 (1.3) 1/421 (0.2) 0.082
Ongoing respiratory symptoms, n/N (%) 47/944 (5.0) 43/523 (8.2) 4/421 (1.0) <0.001
Need for home oxygen therapy, n/N (%) 5/944 (0.5) 5/523 (1.0) 0/421 (0.0) 0.069
Re-hospitalization for any reason, n/N (%) 71/944 (7.5) 41/523 (7.8) 30/421 (7.1) 0.679
Lower respiratory tract infection, n/N (%) 12/944 (1.3) 10/523 (1.9) 2/421 (0.5) 0.050
Urinary tract infection, n/N (%) 47/944 (5.0) 26/523 (5.0) 21/421 (5.0) 0.991
Acute rejection (biopsy proven), n/N (%) 10/944 (1.1) 6/523 (1.1) 4/421 (1.0) 1.000
Venous or arterial thromboembolic event, n/N (%) 5/944 (0.5) 5/523 (1.0) 0/421 (0.0) 0.069
CMV infection/disease, n/N (%) 8/944 (0.8) 6/523 (1.1) 2/421 (0.5) 0.310
BK virus infection, n/N (%) 13/944 (1.4) 6/523 (1.1) 7/421 (1.7) 0.499
Hematuria, n/N (%) 40/369 (10.8) 22/195 (11.3) 18/174 (10.3) 0.773
Pyuria, n/N (%) 65/368 (17.7) 35/195 (17.9) 30/173 (17.3) 0.879
BMI (kg/m2), median (IQR) 25.6 (23.4–27.9) 25.7 (24.1–28.3) 25.5 (22.7–27.5) 0.133
Systolic blood pressure, mmHg, median (IQR) 130.0 (120.0–132.0) 130.0 (120.0–132.0) 130.0 (120.0–134.0) 0.890
Diastolic blood pressure, mmHg, median (IQR) 80.0 (70.0–85.0) 80.0 (70.0–84.0) 80.0 (75.0–85.0) 0.501
Creatinine, mg/dL, median (IQR) 1.3 (1.0–1.7) 1.3 (1.0–1.7) 1.2 (1.0–1.6) 0.230
Albumin, g/dL, median (IQR) 4.2 (4.0–4.5) 4.2 (3.9–4.5) 4.2 (4.0–4.5) 0.527
CRP, mg/L, median (IQR) 3.3 (2.0–6.0) 4.1 (2.5–7.4) 3.0 (2.0–5.0) 0.021
Hemoglobin, g/dL, median (IQR) 12.9 (11.4–14.2) 12.8 (11.2–14.1) 13.0 (11.7–14.4) 0.005
Proteinuria, mg/mg, median (IQR) 234.0 (115.1–600.0) 257.5 (115.0–616.0) 201.5 (115.5–458.1) 0.434

P-values presented from the Chi-squared test, Fisher's exact test, or Mann–Whitney U test.

IQR, interquartile range; BMI, body mass index; CMV, cytomegalovirus; CRP, C-reactive protein.